BTL Industries Reports Over $850 Million in Global Revenue and Looks to Accelerate North American Growth by 2026

BTL Industries Sees Revenue Surge and Future Growth

BTL Industries, a prominent player in the medical device sector, recently held its North American Sales Meeting, which saw participation from over 350 representatives across the U.S. and Canada. This event served to celebrate a year marked by impressive results and to set a clear roadmap for the future, particularly in the year 2026.

The meeting revealed that BTL has achieved a remarkable milestone, surpassing $850 million in global revenue. This achievement reflects the company’s strong market presence, particularly in North America, where demand for wellness, aesthetics, and mental health solutions is flourishing. BTL's established portfolio has demonstrated significant growth in these areas, indicating its robust position in the market.

In addition to celebrating current successes, BTL's leadership emphasized their commitment to strategic expansion. The company plans to bolster its workforce in North America by bringing in talent across various sectors, including commercial, clinical, and operational roles. This strategic move is a response to the rising demand in the market, which is expected to continue driving growth across key areas.

One of the key highlights shared during the meeting was BTL's intent to venture into new service areas. The company recently received regulatory approval in Canada for a revolutionary dry eye treatment, expanding its offerings in ophthalmology—a segment that showcases BTL's commitment to addressing critical health issues with innovative solutions.

Furthermore, 2026 will mark the launch of EMVITAL, an advanced functional laser platform incorporating BTL's proprietary TriHIL technology. EMVITAL is engineered to provide precise, non-invasive tissue heating, offering relief from muscle and joint discomfort. With approvals already in place for inflammation-related indications, this launch signals a promising addition to BTL's expanding portfolio.

David Chmel, the CEO of BTL North America, shared insights into the company’s strategy moving forward. “Our results in North America reflect the strength of our core portfolio, disciplined execution, and our ability to scale effectively across multiple clinical segments,” he stated. He further conveyed optimism about 2026, attributing future growth to ongoing innovation, regulatory advancements, and investments in human resources.

Founded in 1993, BTL Industries has emerged as a leader in medical technology, boasting a portfolio that spans aesthetic medicine, rehabilitation, and much more. With a commitment to leveraging science and technology, BTL continues to shape the landscape of non-invasive and therapeutic medical treatments. The company holds over 200 patents, supported by a dedicated team of more than 600 engineers, all working to deliver groundbreaking solutions worldwide.

As BTL looks to the future—grounded in achievements and optimistic for growth—the North American market remains a focal point, anticipated to drive significant advancements in medical technology and patient care in the coming years. With robust growth strategies and a deepened commitment to innovation, BTL Industries is poised to further solidify its role as a leader in the medical device industry.